About Us

NEX-I, First-In-Class Cancer Immunotherapy Development Company

History

2023

05
  • [ONCOKINE® Discovery Platform] Published Nature Communications (IF=17.6) Overcoming the resistance of cisplatin treatment through autophagy inhibition
04
  • Awarded for government initiative program, “All-stage Pharmaceutical industry global expansion” by KHIDI
  • Awarded for government initiative program, “Unconquerable Startups 1000+ Project” by the Ministry of SMEs and Startups
03
  • MOU signed - Joint research agreement for AI-driven development of new antibody with Arontier Co., Ltd.

2022

2021